PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Carton for 3 ml, 10 ml, 15 ml and 30 ml}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Meloxicam-Boehringer 0.5 mg/ml oral suspension for cats and guinea pigs

2. STATEMENT OF ACTIVE SUBSTANCES

Meloxicam: 0.5 mg/ml

3. PACKAGE SIZE

3 ml
10 ml
15 ml
30 ml

4. TARGET SPECIES

Cats and guinea pigs

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Shake well before use.
Oral use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

3 ml: Once opened use within 14 days
10 ml: Once opened use within 6 months.
15 ml: Once opened use within 6 months.
30 ml: Once opened use within 6 months.

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Animal Health UK Limited

14. MARKETING AUTHORISATION NUMBER

Vm 08327/5040

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS {Bottle, 3 ml, 10 ml, 15 ml, 30 ml}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Meloxicam-Boehringer 0.5 mg/ml for cats and guinea pigs

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Meloxicam: 0.5 mg/ml

3 ml
10 ml
15 ml
30 ml

Shake well before oral use.

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

3 ml: Once opened use within 14 days
10 ml: Once opened use within 6 months.
15 ml: Once opened use within 6 months.
30 ml: Once opened use within 6 months.

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Meloxicam-Boehringer 0.5 mg/ml oral suspension for cats and guinea pigs

2. Composition

Each ml contains:
Active substance: Meloxicam: 0.5 mg (equivalent to 0.017 mg per drop).
Excipient: Sodium benzoate: 1.5 mg (equivalent to 0.05 mg per drop)

Yellowish viscous oral suspension with a green tinge.

3. Target species

Cats and guinea pigs

4. Indications for use

Cats:
Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.
Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders in cats.

Guinea pigs:
Alleviation of mild to moderate post-operative pain associated with soft tissue surgery such as male castration.

5. Contraindications

Do not use in cats suffering from gastrointestinal disorders such as irritation or haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use in cats less than 6 weeks of age.
Do not use in guinea pigs less than 4 weeks of age.

6. Special warnings

Special precautions for safe use in the target species:
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
Post-operative use in cats and guinea pigs:
In case additional pain relief is required, multimodal pain therapy should be considered.

Chronic musculoskeletal disorders in cats:
Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.
This veterinary medicinal product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

Pregnancy and lactation
Do not use in pregnant or lactating animals.

Interaction with other medicinal products and other forms of interaction:
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. The veterinary medicinal product must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided.

In cats, pre-treatment with anti-inflammatory substances other than Metacam solution for injection at a single dose of 0.2 mg/kg may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment.

The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

Overdose:
Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels.
In case of overdose, adverse reactions, as listed in section "Adverse reactions", are expected to be more severe and more frequent. In case of overdose symptomatic treatment should be initiated.

In guinea pigs, an overdose of 0.6 mg/kg body weight administered during 3 days followed by a dose of 0.3 mg/kg during 6 additional days did not cause adverse events typical for meloxicam. The safety of doses exceeding 0.6 mg/kg has not been evaluated in guinea pigs.

Major incompatibilities:
None known.

7. Adverse events

Cats:

Very rare (< 1 animal in 10,000 animals treated, including isolated reports):

- Appetite loss[1], lethargy[1]
- Vomiting[1], diarrhoea[1], blood in faeces[1,2], haemorrhagic diarrhoea[1], haematemesis[1], gastric ulcer[1], small intestinal ulcer[1]
- Elevated liver enzymes[1]
- Renal failure[1]

[1] These adverse events occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
[2] Occult.

Guinea pigs: None.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder, the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system:
Email: adverse.events@vmd.gov.uk.
Website: https://www.gov.uk/report-veterinary-medicine-problem.

8. Dosage for each species, routes and method of administration

Oral use.

Cats:
Post-operative pain and inflammation following surgical procedures:
After initial treatment with the veterinary medicinal product with a starting dosage of 0.2 mg/kg, continue treatment 24 hours later with the veterinary medicinal product at a dosage of 0.05 mg meloxicam/kg body weight. The oral follow-up dose may be administered once daily (at 24-hour intervals) for up to 4 days.

Acute musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a dose of 0.05 mg meloxicam/kg body weight for as long as acute pain and inflammation persist.

Chronic musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight.
A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent.

Dosing procedure using the drop dispenser of the bottle:
Dose of 0.2 mg meloxicam/kg body weight: 12 drops/kg body weight
Dose of 0.1 mg meloxicam/kg body weight: 6 drops/kg body weight
Dose of 0.05 mg meloxicam/kg body weight: 3 drops/kg body weight.

Dosing procedure using the measuring syringe:
The syringe fits onto the drop dispenser of the bottle and has a kg-body weight scale which corresponds to the dose of 0.05 mg meloxicam/kg bodyweight. Thus for initiation of the treatment of chronic musculo-skeletal disorders on the first day, twice the maintenance volume will be required.
For initiation of the treatment of acute musculo-skeletal disorders on the first day, 4 times the maintenance volume will be required.

To be administered orally either mixed with food or directly into the mouth.
The suspension can be given using the drop dispenser of the bottle for cats of any body weight. Alternatively and for cats with a body weight of at least 2 kg, the measuring syringe provided in the package can be used. The recommended dose should not be exceeded. Wash the measuring syringe with water and dry prior to the next use.

Shake bottle well. Push down and unscrew bottle top. Attach the dosing syringe to the drop dispenser of the bottle by gently pushing.



Turn the bottle/syringe upside down. Pull the plunger out until the black line on the plunger corresponds to your cat´s body weight in kilograms.



Turn the bottle right way up and with a twisting movement separate the dosing syringe from the bottle.



By pushing the plunger in empty the contents of the syringe onto the food or directly into the mouth.

Guinea pigs:
Post-operative pain associated with soft tissue surgery:
Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on day 1 (pre-surgery). Treatment is to be continued once daily by oral administration (at 24-hours intervals) at a dose of 0.1 mg meloxicam/kg body weight on day 2 to day 3 (post-surgery).

The dose can, at the discretion of the veterinarian, be titrated up to 0.5 mg/kg in individual cases. The safety of doses exceeding 0.6 mg/kg has, however, not been evaluated in guinea pigs.

The suspension should be given directly into the mouth using a standard 1 ml syringe graduated with ml scale and 0.01 ml increments.

Dose of 0.2 mg meloxicam/kg body weight: 0.4 ml/kg body weight
Dose of 0.1 mg meloxicam/kg body weight: 0.2 ml/kg body weight

Use a small container (e.g. a teaspoon) and drop the veterinary medicinal product into the container (it is advised to dispense a few drops more than required into the small container). Use a standard 1 ml syringe to draw up the veterinary medicinal product according to the bodyweight of the guinea pig. Administer the veterinary medicinal product with the syringe directly into the mouth of the guinea pig. Wash the small container with water and dry prior to the next use.

Do not use the cat syringe with the kg-body weight scale and the cat pictogram for guinea pigs.

Shake bottle well. Push down and unscrew bottle top.

Use a small container (e.g. a teaspoon) and drop Meloxicam-Boehringer oral suspension into the container (it is advised to dispense a few drops more than required into the small container).



Use the 1 ml standard syringe and draw up the required volume of Meloxicam-Boehringer oral suspension which corresponds to the body weight of the guinea pig.



By pushing the plunger in empty the contents of the syringe directly into the mouth of the guinea pig.

9. Advice on correct administration

Particular care should be taken with regard to the accuracy of dosing. To ensure a correct dosage, body weight should be determined as accurately as possible. The use of suitably calibrated measuring equipment is recommended. Shake well before use.
Please carefully follow the instructions of the veterinarian.
Avoid introduction of contamination during use.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.

Shelf life after first opening the container:
3 ml bottle: 14 days
10 ml, 15 ml and 30 ml bottles: 6 months.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the vial after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.
Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 08327/5040

Cardboard box with one bottle of either 3 ml, 10 ml, 15 ml or 30 ml.

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release:
Boehringer Ingelheim Animal Health UK Limited
Ellesfield Avenue
Bracknell
Berkshire
RG12 8YS

Local representatives and contact details to report suspected adverse reactions:
United Kingdom (Great Britain)
Boehringer Ingelheim Animal Health UK Limited
+44 1344 746957

17. Other information

POM-V	Veterinary medicinal product subject to prescription

For animal treatment only

Gavin Hall
Approved: 30 June 2025